1. 411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients. (9th November 2020) Authors: El-Khoueiry, Anthony; Thomas, Jacob; Olszanski, Anthony; Azad, Nilofer; Bender, Lewis; Walters, Ian; Whalen, Giles; Hanna, Diana; Ingham, Matthew; Siu, Lilian Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients. (9th November 2020) Authors: El-Khoueiry, Anthony; Thomas, Jacob; Olszanski, Anthony; Azad, Nilofer; Bender, Lewis; Walters, Ian; Whalen, Giles; Hanna, Diana; Ingham, Matthew; Siu, Lilian Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A436 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma. (2021) Authors: Doshi, Sahil D.; Oza, Jay; Remotti, Helen; Remotti, Fabrizio; Moy, Matthew P.; Schwartz, Gary K.; Ingham, Matthew Journal: JCO precision oncology Issue: Volume 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma. (8th January 2021) Authors: Doshi, Sahil D.; Oza, Jay; Remotti, Helen; Remotti, Fabrizio; Moy, Matthew P.; Schwartz, Gary K.; Ingham, Matthew Journal: JCO precision oncology Issue: Volume 5(2021) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation‐Associated Sarcoma. (December 2021) Authors: Doshi, Sahil D.; Oza, Jay; Remotti, Helen; Remotti, Fabrizio; Moy, Matthew P.; Schwartz, Gary K.; Ingham, Matthew Journal: JCO precision oncology Issue: Volume 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients. Issue 1 (4th June 2020) Authors: Trager, Megan H; Coley, Shana M; Dube, Geoffrey; Khan, Shaheer; Ingham, Matthew; Samie, Faramarz H; Geskin, Larisa J; McDonnell, Diana; Brouder, Daniel; Saenger, Yvonne; Carvajal, Richard Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗